Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) CEO Lawrence Klein sold 25,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $95.60, for a total transaction of $2,390,000.00. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares in the company, valued at $88,251,036.80. This trade represents a 2.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Lawrence Otto Klein also recently made the following trade(s):
- On Thursday, October 1st, Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $83.62, for a total transaction of $2,090,500.00.
- On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $234,680.92.
- On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00.
Oruka Therapeutics Stock Up 4.3%
Shares of ORKA stock opened at $99.55 on Wednesday. Oruka Therapeutics, Inc. has a 52 week low of $25.23 and a 52 week high of $115.51. The firm’s 50-day simple moving average is $88.17 and its two-hundred day simple moving average is $69.56.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Research analysts expect that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.
Analysts Set New Price Targets
ORKA has been the subject of several research reports. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 19th. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Wedbush reaffirmed an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Finally, Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.
Check Out Our Latest Research Report on Oruka Therapeutics
Hedge Funds Weigh In On Oruka Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. Ethic Inc. boosted its position in shares of Oruka Therapeutics by 12.3% during the 3rd quarter. Ethic Inc. now owns 3,329 shares of the company’s stock valued at $277,000 after acquiring an additional 364 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in shares of Oruka Therapeutics by 3.4% during the third quarter. AlphaCentric Advisors LLC now owns 6,752 shares of the company’s stock worth $562,000 after purchasing an additional 221 shares in the last quarter. Alps Advisors Inc. grew its holdings in shares of Oruka Therapeutics by 43.8% during the third quarter. Alps Advisors Inc. now owns 87,745 shares of the company’s stock worth $7,308,000 after purchasing an additional 26,731 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Oruka Therapeutics in the third quarter worth approximately $282,000. Finally, Profund Advisors LLC increased its position in shares of Oruka Therapeutics by 12.0% in the third quarter. Profund Advisors LLC now owns 24,649 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,637 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.
About Oruka Therapeutics
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.
Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
